Literature DB >> 28462920

Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.

S M Baxi1,2, R M Greenblatt1,3,4, P Bacchetti4, M Cohen5, J A DeHovitz6, K Anastos7, S J Gange8, M A Young9, B E Aouizerat3,10,11.   

Abstract

Higher exposure to tenofovir (TFV) increases the risk for kidney function decline, but the impact of genetic factors on TFV exposure is largely unknown. We investigated whether single-nucleotide polymorphisms (SNPs, n=211) in 12 genes are potentially involved in TFV exposure. Participants (n=91) from the Women's Interagency HIV Study, underwent a 24 h intensive pharmacokinetic sampling of TFV after witnessed dose and TFV area under the time-concentration curves (AUCs) were calculated for each participant. SNPs were assayed using a combination of array genotyping and Sanger sequencing. Linear regression models were applied to logarithmically transformed AUC. Those SNPs that met an a priori threshold of P<0.001 were considered statistically associated with TFV AUC. ABCG2 SNP rs2231142 was associated with TFV AUC with rare allele carriers displaying 1.51-fold increase in TFV AUC (95% confidence interval: 1.26, 1.81; P=1.7 × 10-5). We present evidence of a moderately strong effect of the rs2231142 SNP in ABCG2 on a 24 h TFV AUC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28462920     DOI: 10.1038/tpj.2017.3

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  53 in total

1.  A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications.

Authors:  Indrani Halder; Mark Shriver; Matt Thomas; Jose R Fernandez; Tony Frudakis
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

Review 2.  ABCG2: structure, function and role in drug response.

Authors:  Orsolya Polgar; Robert W Robey; Susan E Bates
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-01       Impact factor: 4.481

3.  Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Antonio D'avolio; Pablo Barreiro; Marta Albalate; Eugenia Vispo; Carmen Solera; Marco Siccardi; Stefano Bonora; Giovanni Di Perri; Vincent Soriano
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

4.  Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.

Authors:  Leonardo Calza; Filippo Trapani; Sara Tedeschi; Benedetta Piergentili; Roberto Manfredi; Vincenzo Colangeli; Pierluigi Viale
Journal:  Scand J Infect Dis       Date:  2011-04-01

5.  Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Vincent Soriano; Deirdre Egan; Marta Albalater; Judit Morello; Lorena Cuenca; Gema González-Pardo; Saye Khoo; David Back; Andrew Owen
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

6.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Authors:  Jennifer J Kiser; Courtney V Fletcher; Patricia M Flynn; Coleen K Cunningham; Craig M Wilson; Bill G Kapogiannis; Hanna Major-Wilson; Rolando M Viani; Nancy X Liu; Larry R Muenz; D Robert Harris; Peter L Havens
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

7.  The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Authors:  J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher
Journal:  Clin Pharmacol Ther       Date:  2007-06-27       Impact factor: 6.875

8.  Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study.

Authors:  Lili Zhang; Kylee L Spencer; V Saroja Voruganti; Neal W Jorgensen; Myriam Fornage; Lyle G Best; Kristin D Brown-Gentry; Shelley A Cole; Dana C Crawford; Ewa Deelman; Nora Franceschini; Angelo L Gaffo; Kimberly R Glenn; Gerardo Heiss; Nancy S Jenny; Anna Kottgen; Qiong Li; Kiang Liu; Tara C Matise; Kari E North; Jason G Umans; W H Linda Kao
Journal:  Am J Epidemiol       Date:  2013-04-03       Impact factor: 4.897

9.  Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Authors:  Takeshi Nishijima; Hirokazu Komatsu; Hiroyuki Gatanaga; Takahiro Aoki; Koji Watanabe; Ei Kinai; Haruhito Honda; Junko Tanuma; Hirohisa Yazaki; Kunihisa Tsukada; Miwako Honda; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

10.  Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

Authors:  Andrew Hill; Saye Khoo; David Back; Anton Pozniak; Marta Boffito
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

View more
  3 in total

1.  Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.

Authors:  Mengbi Yang; Xin Xu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-09-09       Impact factor: 4.936

Review 2.  Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.

Authors:  Willy Albert Flegel; Kshitij Srivastava; Tristan Michael Sissung; Barry Ronald Goldspiel; William Douglas Figg
Journal:  Vox Sang       Date:  2020-09-30       Impact factor: 2.996

3.  Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid.

Authors:  Eric H Decloedt; Phumla Z Sinxadi; Lubbe Wiesner; John A Joska; David W Haas; Gary Maartens
Journal:  South Afr J HIV Med       Date:  2021-04-28       Impact factor: 2.744

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.